Neurocrine Biosciences (NASDAQ:NBIX) Releases Quarterly Earnings Results, Beats Expectations By $0.31 EPS

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported $1.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.13 by $0.31, Briefing.com reports. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The business had revenue of […]

Related Keywords

Kevin Charles Gorman ,Stifel Nicolaus ,Neurocrine Biosciences ,Darin Lippoldt ,Nasdaq ,Cantor Fitzgerald ,Neurocrine Biosciences Company Profile ,Meiji Yasuda Asset Management Co Ltd ,Mercer Global Advisors Inc ,Commonwealth Equity Services ,Neurocrine Biosciences Inc ,First Republic Investment Management Inc ,Wells Fargo Company ,Get Free Report ,Biosciences Trading Down ,Charles Gorman ,Financial Advisors ,Republic Investment Management ,Global Advisors ,Equity Services ,Neurocrine Biosciences Daily ,Nasdaq Nbix ,Nbix ,Medical ,64125c10 ,Earnings ,